222 related articles for article (PubMed ID: 17082512)
21. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
Haidar A; Jønler M; Folkmar TB; Lund L
Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
24. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
[TBL] [Abstract][Full Text] [Related]
25. [Osteonecrosis associated with the use of biphosphonates: Case report].
Anguita C T; Agurto P J; Roa E I; Laissle C G
Rev Med Chil; 2006 Sep; 134(9):1161-5. PubMed ID: 17171218
[TBL] [Abstract][Full Text] [Related]
26. Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.
Van den Wyngaert T; Huizing MT; Fossion E; Vermorken JB
Oral Oncol; 2010 Mar; 46(3):214-8. PubMed ID: 20138570
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates and osteonecrosis of the jaw: a case report.
Reiriz AB; De Zorzi Pde M; Lovat CP
Clinics (Sao Paulo); 2008 Apr; 63(2):281-4. PubMed ID: 18438586
[No Abstract] [Full Text] [Related]
28. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
29. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
[TBL] [Abstract][Full Text] [Related]
30. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
31. [Avascular osteonecrosis of the jaws induced by diphosphonates].
Lannoy D; Decaudin B; Barrier F; Bemba M; Wierre L; Pignon JM; Horrent S; Résibois JP; Wetterwald M; Odou P
Therapie; 2006; 61(4):363-5. PubMed ID: 17124954
[No Abstract] [Full Text] [Related]
32. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
33. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
Rathbone EJ; Brown JE; Marshall HC; Collinson M; Liversedge V; Murden GA; Cameron D; Bell R; Spensley S; Agrawal R; Jyothirmayi R; Chakraborti P; Yuille F; Coleman RE
J Clin Oncol; 2013 Jul; 31(21):2685-91. PubMed ID: 23796998
[TBL] [Abstract][Full Text] [Related]
34. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.
Junquera L; Gallego L; Cuesta P; Pelaz A; de Vicente JC
Am J Otolaryngol; 2009; 30(6):390-5. PubMed ID: 19880027
[TBL] [Abstract][Full Text] [Related]
35. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Hoefert S; Schmitz I; Tannapfel A; Eufinger H
Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
[TBL] [Abstract][Full Text] [Related]
36. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
[TBL] [Abstract][Full Text] [Related]
37. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
38. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
Ficarra G; Beninati F
Head Neck Pathol; 2007 Dec; 1(2):132-40. PubMed ID: 20614264
[TBL] [Abstract][Full Text] [Related]
40. Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.
Uña E
BMJ Case Rep; 2012 Mar; 2012():. PubMed ID: 22605820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]